SCHEDULE: Yap Kim Choy Boosts Cyclacel Stake to 20.76% with Warrants

Malaysian investor Yap Kim Choy has significantly increased beneficial ownership in Cyclacel Pharmaceuticals, Inc. to 20.76% through common stock and various series of warrants.

Summary

• Yap Kim Choy, a Malaysian individual, reported beneficial ownership of 872,000 shares of Cyclacel Pharmaceuticals, Inc. common stock.
• This ownership represents 20.76% of the company's outstanding common stock.
• The stake comprises 218,000 shares of common stock and 654,000 shares underlying three series of warrants (218,000 Series A, 218,000 Series B, and 218,000 Series C warrants).
• The warrants have an initial exercise date of June 20, 2025, and a termination date of June 20, 2030.
• Exercise prices for the warrants are $7.65 per share for Series A, $9.00 per share for Series B, and $10.20 per share for Series C.
• The reporting person certified that the securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The filing indicates a significant, long-term investment by an individual, which can be seen as a positive sign of confidence in the company's future. The warrant structure provides potential future capital. However, it's a disclosure of ownership, not operational performance, so the sentiment is moderately positive due to the implied investor confidence and future capital potential.

Positives

• A significant individual investor, Yap Kim Choy, has increased his stake, potentially signaling confidence in Cyclacel Pharmaceuticals' future prospects.
• The acquisition of warrants provides potential future capital infusion for the company upon their exercise, supporting ongoing operations or development.
• The warrants include provisions for cashless exercise, offering flexibility to the holder and potentially reducing immediate cash outflow for the investor.

Risks

• The value of the warrants is contingent on Cyclacel Pharmaceuticals' common stock price exceeding the respective exercise prices ($7.65, $9.00, $10.20) for the warrants to be in-the-money and economically viable to exercise.
• Potential for dilution for existing shareholders if all 654,000 warrant shares are exercised, increasing the total number of outstanding shares.
• The company faces a risk of penalties if it fails to timely deliver warrant shares upon exercise, including liquidated damages of $10 to $20 per Trading Day for each $1,000 of Warrant Shares subject to exercise.

Future Outlook

The exercise of the outstanding warrants by Yap Kim Choy could provide future capital to Cyclacel Pharmaceuticals, Inc. The company has committed to reserving sufficient authorized and unissued common stock for warrant exercises and ensuring valid, fully paid, and non-assessable issuance of shares.

Management Comments

• The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
• The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.
• The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.
• The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

Industry Context

This filing indicates a significant individual investment in a pharmaceutical company, which is common in the biotechnology and pharmaceutical sectors where long-term capital and investor confidence are crucial for R&D and commercialization efforts. The structure of the investment, combining common stock with warrants, suggests a staged investment approach, potentially aligning with development milestones or market performance.

Comparison to Industry Standards

• The beneficial ownership of 20.76% by a single individual is a substantial stake, often seen in early-stage or smaller biotechnology companies where a key investor can exert significant influence.
• The use of multi-series warrants with escalating exercise prices (e.g., $7.65, $9.00, $10.20) is a common financing mechanism in the biotech industry, allowing companies to raise capital incrementally as their valuation potentially increases with progress in clinical trials or product development.
• The inclusion of cashless exercise provisions in the warrants is a standard feature designed to provide flexibility to warrant holders, especially in situations where a registration statement for the underlying shares might not be immediately effective.

Stakeholder Impact

• Shareholders: Potential for future dilution if warrants are exercised, but also potential for increased capital for the company. The significant stake by Yap Kim Choy could influence corporate decisions.
• Company: Benefits from potential future capital infusion upon warrant exercise, supporting operations or development.

Next Steps

• Potential exercise of Series A, B, and C warrants by Yap Kim Choy between June 20, 2025, and June 20, 2030.
• Cyclacel Pharmaceuticals, Inc. must reserve sufficient common stock for the issuance of warrant shares.
• Cyclacel Pharmaceuticals, Inc. must ensure all warrant shares are duly authorized, validly issued, fully paid, and non-assessable upon exercise.

Key Dates

Recommendation

The filing primarily discloses a significant beneficial ownership stake and the terms of associated warrants. While the substantial investment by Yap Kim Choy and the potential for future capital infusion from warrant exercises are positive indicators of investor confidence, the filing does not provide new operational or financial performance data to warrant a 'buy' or 'strong buy' recommendation. The future impact depends on the company's performance and the actual exercise of warrants. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current positions while monitoring future developments and the company's operational results.

Keywords

Cyclacel Pharmaceuticals, Yap Kim Choy, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Equity Investment, Shareholder Disclosure, Biotechnology, Pharmaceuticals